Cynata Therapeutics (ASX:CYP) reported positive efficacy data observed in preclinical studies conducted with the firm's Cymerus induced pluripotent stem cell-derived mesenchymal stem cells in models of ischaemic heart disease, according to a Monday Australian bourse filing.
The firm studied a minimally invasive method to deliver beneficial molecules from mesenchymal stem cells over an extended period, using a retrievable encapsulation device.
The treatment in a rat model of heart attack resulted in improved heart function and a reduction in harmful structural changes in the heart compared to controls treated with encapsulated placebo. It also resulted in less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups.
In an in vitro model of human heart tissues created and grown in a laboratory, the treatment resulted in improved survival and function compared with controls treated with placebo.
The study team submitted a manuscript describing the study to a leading peer-reviewed journal.
Its shares fell over 9% on market close on Monday, falling to its lowest point in over a year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。